Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes.
PMID: 34319801
2021
Journal of clinical microbiology
Abstract: Multiple-point mt, including rtL180M-rtM204V- rtN238A and rtL180M-rtM204I, were identified in only two children, resulting in LMV-ADF resistance and reduced ETV susceptibility.
Abstract: We developed a novel real-time PCR assay that simultaneously evaluates 11 major nucleos(t)ide antiviral (NA) drug resistance mutations (mt) in chronic hepatitis B patients (CHB), including L180M, M204I/V, and V207M (lamivudine [LMV]
Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations.
PMID: 34755817
2021
Revista do Instituto de Medicina Tropical de Sao Paulo
Abstract: Resistance mutations (rtM204V/I/S) associated or not with compensatory mutations (rtL180M, rtV173L) were identified in 13.9% (5/36) of patients undergoing viral treatment and 1.1% (1/90) of naive patients.
Result: In the group of patients undergoing treatment, strains of HBV with resistance mutations (rtM204V/I/S) associated or not with compensatory mutations (rtL180M, rtV173L) were identified in 13.9% (5/36) of the analyzed samples.
Result: In the group of patients who were not undergoing treatment, 1.1% (1/90) of the samples pr
Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients.
Introduction: Phenotypic studies showed that the LMV resistance arising from rtM204V/I in the YMDD motif, could negate sensitivity to LMV by more than 100-fold decrease compared with wild-type.
Introduction: The classic ETV resistance mutations rtT184G/rtS202I/rtM250V will reduce susceptibility to ETV, only in conjunction with additional LMV resistance mutations, such as rtM204V/I.
Method: Three different mutations, rtM204V, rtL229V and
Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Abstract: CONCLUSION: An rtL180M/T184L/A200V/M204V mutant with moderate resistance to TDF monotherapy was selected during sequential nucleoside analogue (NA) treatment in a stepwise manner.
Abstract: In vitro phenotyping demonstrated that the rtL180M/T184L/A200V/M204V mutant had moderate resistance to TDF treatment, with a 4.52-fold higher half maximal effective concentration than that of wild-type virus.
Abstract: METHODS AND RESULTS: Here, we report viral rebound in a patient with chronic hepatitis B who underwent TDF monotherapy and harboured a quadruple mutant consisting of cla
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Result: In fact, M184V in HIV-1 (or M204V in HBV) is not reportedly associated with TDF/TAF resistance.
Result: One possible solution to overcome M184V/I (M204V/I in HBV) resistance is to decrease composition for NRTIs that do not rely on the interactions with Met184.
Result: Previous in vitro antiviral assays have demonstrated that 4'-cyano-containing NRTIs, such as CAdA and CdG, show slightly decreased but moderate activity against HBV with M204V in RT.
Result: The corresponding M204V/I mutation
7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Abstract: Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the production of HBVWT (IC50 = 153.7 nM), entecavir (ETV)-resistant HBV carrying L180M/S202G/M204V substitutions (HBVETVR; IC50 = 373.2 nM), and adefovir dipivoxil (ADV)-resistant HBV carrying A181T/N236T substitutions (HBVADVR; IC50=192.6 nM), whereas ETV and ADV were less potent against HBVETVR and HBVADVR (IC50: >1,000 and 4,022.5 nM, respectively).
Method: Plasmids carrying the 1.24-fold HBV genomes of a wild-type genotype Ce strain (HBVWTCe), entecavir-resistant strain carrying L180M/S202G/M204V substitutions (HBVETVR), or adefovir-resistant strain carrying
Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
Abstract: Several lamivudine-associated HBV resistance mutations, including L180M, A181T, M204I, and M204V, were observed.
Result: Analysis of polymerase gene sequences from baseline and follow-up samples showed the presence of resistance-associated mutations in 5 of these 6 patients, including L180M, A181T, M204I, and M204V (Table 5).
Result: Patient ZA113 had the L180M mutation and the L180M + M204V mutations at the 12- and 18-month follow-up visits, respectively, with HBV viremia increasing from 1.99 x 104 IU/mL at baseline to 7.08 x 106 at the 18-month follow-
Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Abstract: Three HBV isolates (8.3%) were identified with drug resistance mutations to lamivudine, entericavir, telbivudine and tenofovir, which are amino acid substitutions in the HBV polymerase gene at positions L180M, T184A, M204V.
Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.
Method: According to the most recent clinical practice guidelines of the European Association for the Study of the Liver, the following amino acid substitution profiles for HBV-resistant mutants were used: rtM204V/I (LAM resistance), rtM204I or L180M + rtM204V (LdT resistance), rtA181T/V or rtN236T (ADV resistance), rtL180M + rtM204I/V +- rtT184S/G +-
HBV mutation literature information.
PMID: 
2021
Journal of clinical microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT